CRNX
Price
$46.03
Change
+$1.32 (+2.95%)
Updated
Nov 26 closing price
Capitalization
4.37B
96 days until earnings call
Intraday BUY SELL Signals
MDGL
Price
$601.03
Change
+$8.99 (+1.52%)
Updated
Nov 26 closing price
Capitalization
13.65B
96 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

CRNX vs MDGL

Header iconCRNX vs MDGL Comparison
Open Charts CRNX vs MDGLBanner chart's image
Crinetics Pharmaceuticals
Price$46.03
Change+$1.32 (+2.95%)
Volume$990.62K
Capitalization4.37B
Madrigal Pharmaceuticals
Price$601.03
Change+$8.99 (+1.52%)
Volume$254.38K
Capitalization13.65B
CRNX vs MDGL Comparison Chart in %
CRNX
Daily Signal:
Gain/Loss:
MDGL
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
CRNX vs. MDGL commentary
Nov 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRNX is a StrongBuy and MDGL is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Nov 28, 2025
Stock price -- (CRNX: $46.03 vs. MDGL: $601.03)
Brand notoriety: CRNX and MDGL are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRNX: 57% vs. MDGL: 72%
Market capitalization -- CRNX: $4.37B vs. MDGL: $13.65B
CRNX [@Biotechnology] is valued at $4.37B. MDGL’s [@Biotechnology] market capitalization is $13.65B. The market cap for tickers in the [@Biotechnology] industry ranges from $109.65B to $0. The average market capitalization across the [@Biotechnology] industry is $2.2B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRNX’s FA Score shows that 0 FA rating(s) are green whileMDGL’s FA Score has 1 green FA rating(s).

  • CRNX’s FA Score: 0 green, 5 red.
  • MDGL’s FA Score: 1 green, 4 red.
According to our system of comparison, MDGL is a better buy in the long-term than CRNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRNX’s TA Score shows that 3 TA indicator(s) are bullish while MDGL’s TA Score has 6 bullish TA indicator(s).

  • CRNX’s TA Score: 3 bullish, 4 bearish.
  • MDGL’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, MDGL is a better buy in the short-term than CRNX.

Price Growth

CRNX (@Biotechnology) experienced а +7.30% price change this week, while MDGL (@Biotechnology) price change was +8.18% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was -1.24%, and the average quarterly price growth was +71.95%.

Reported Earning Dates

CRNX is expected to report earnings on Mar 04, 2026.

MDGL is expected to report earnings on Mar 04, 2026.

Industries' Descriptions

@Biotechnology (+4.76% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MDGL($13.7B) has a higher market cap than CRNX($4.37B). MDGL YTD gains are higher at: 94.779 vs. CRNX (-9.975). MDGL has higher annual earnings (EBITDA): -266.74M vs. CRNX (-419.62M). CRNX has more cash in the bank: 1.2B vs. MDGL (797M). CRNX has less debt than MDGL: CRNX (49.9M) vs MDGL (124M). MDGL has higher revenues than CRNX: MDGL (516M) vs CRNX (1.39M).
CRNXMDGLCRNX / MDGL
Capitalization4.37B13.7B32%
EBITDA-419.62M-266.74M157%
Gain YTD-9.97594.779-11%
P/E RatioN/AN/A-
Revenue1.39M516M0%
Total Cash1.2B797M150%
Total Debt49.9M124M40%
FUNDAMENTALS RATINGS
CRNX vs MDGL: Fundamental Ratings
CRNX
MDGL
OUTLOOK RATING
1..100
2144
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
65
Fair valued
PROFIT vs RISK RATING
1..100
4715
SMR RATING
1..100
9494
PRICE GROWTH RATING
1..100
4136
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MDGL's Valuation (65) in the Pharmaceuticals Other industry is in the same range as CRNX (86) in the Pharmaceuticals Major industry. This means that MDGL’s stock grew similarly to CRNX’s over the last 12 months.

MDGL's Profit vs Risk Rating (15) in the Pharmaceuticals Other industry is in the same range as CRNX (47) in the Pharmaceuticals Major industry. This means that MDGL’s stock grew similarly to CRNX’s over the last 12 months.

MDGL's SMR Rating (94) in the Pharmaceuticals Other industry is in the same range as CRNX (94) in the Pharmaceuticals Major industry. This means that MDGL’s stock grew similarly to CRNX’s over the last 12 months.

MDGL's Price Growth Rating (36) in the Pharmaceuticals Other industry is in the same range as CRNX (41) in the Pharmaceuticals Major industry. This means that MDGL’s stock grew similarly to CRNX’s over the last 12 months.

MDGL's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as CRNX (100) in the Pharmaceuticals Major industry. This means that MDGL’s stock grew similarly to CRNX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRNXMDGL
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
80%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
78%
Bullish Trend 2 days ago
77%
Advances
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
78%
Declines
ODDS (%)
Bearish Trend 8 days ago
76%
Bearish Trend 8 days ago
80%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
77%
Aroon
ODDS (%)
Bearish Trend 2 days ago
70%
Bullish Trend 2 days ago
80%
View a ticker or compare two or three
Interact to see
Advertisement
CRNX
Daily Signal:
Gain/Loss:
MDGL
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
CNEQ34.550.57
+1.68%
Alger Concentrated Equity ETF
THNQ63.650.56
+0.89%
Robo Global® Artificial Intelligence ETF
EFAD42.070.34
+0.80%
ProShares MSCI EAFE Dividend Growers
JPIB49.060.08
+0.16%
JPMorgan International Bond Opps ETF
USNG27.39N/A
N/A
Amplify Samsung U.S. Natrl Gas InfrasETF

CRNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with XNCR. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
+2.95%
XNCR - CRNX
60%
Loosely correlated
+0.70%
NUVL - CRNX
53%
Loosely correlated
-0.73%
CLDX - CRNX
52%
Loosely correlated
+1.32%
IDYA - CRNX
52%
Loosely correlated
+1.10%
DYN - CRNX
52%
Loosely correlated
+1.78%
More